FOR Roderick “Chuck” Gordon, Christmas isn’t about gifts wrapped in shiny paper—it’s about the laughter of children, the embrace of family, and the precious moments that linger long after the tinsel fades. Gordon’s 2024 soca parang offering, “Family Vibes”, explores the real reason for the season. The Laventille-born calypso crooner pours his soul into an instructive melody that speaks to the heart of what makes a Trini Christmas magical: togetherness. It’s a deeply personal piece, with Gordon’s four-year-old daughter, Imani, lending her sweet voice to the song’s opening lines. Imani, who turns five on Tuesday, was included serendipitously. “I was carrying her to her mother, and I hadn’t recorded the song yet. I was just singing it for her now and then,” Gordon recalled. “A little while after, she sends me a voice note with exactly what the introduction is: ‘Daddy, what song is keep yuh family close?’ The minute I heard that voice note, I said, ‘Click, save. I’m using that as the intro.’” “It came fortuitously,” he added, “but it’s in keeping with the vibes and energy of the song. She’s already demonstrating signs of a genuine interest in the performing arts, so it was nice to give her a debut.” For Gordon, the spirit of Christmas lies in being present: “Christmas is the perfect time to give the greatest gift of all: yourself. It’s about paying attention to your children, creating moments that matter, and letting them know they’re loved—not just through material things but through time, presence, and affection. Your involvement with your child is the most important gift you can give.” The challenges of fatherhood FAMILY TIME: Calypsonian Roderick “Chuck” Gordon with his daughter, Imani, and son, Ayomide, during a recent outing to a water park. Beyond the stage, Gordon’s previous work as a counsellor and social worker at the Children’s Court of Trinidad and Tobago has deepened his understanding of fatherhood. Now based at St Mary’s Children Home in Tacarigua, he acknowledges the pressures many modern fathers face. “Balancing family dynamics, societal expectations, and internal stresses makes it challenging, but time management and prioritising moments with your kids is key,” he stressed. “As a father, artiste, and social worker, I try to make time for my daughter (Imani) and my son (Ayomide). I try to be fully present when we’re together, really connecting and strengthening that bond. Whether it’s studio sessions or rehearsals, I involve them in what I do. That healthy connection is what allows you to maintain influence and provide the kind of discipline, training, and guidance they need.” Gordon also speaks candidly about the effects of absent fathers. “I came through adolescence with a father that was somewhat present but emotionally unavailable, and that left emotional scars. It was traumatic to some degree in terms of the development of self-esteem and motivation. The father figure is the motivating influence, the one that inspires you to action, to want to achieve. The mother creates the structure and discipline that enforces it.” He added: “Absent fathers can leave children, especially young men, stuck—not being able to navigate their emotions or the world effectively. It creates challenges in forming relationships, being trustful, and building a sense of security and identity. A positive male role model, whether it’s a biological father or not, is critical.” Advice for single mothers To single mothers raising children without a present father, Chuck offers heartfelt advice. “It’s an extremely difficult job. It’s really important to lean on any kind of support you have—whether it’s extended family or persons in the community,” he advised. “Grandfathers, uncles, or even mentors from extracurricular activities can provide that male energy, which inspires and motivates in a way that’s different from what the female presence offers.” Recalling his own upbringing, he shared: “I lived with my grandfather for a significant period, and what he represented to me—seeing him work the shop, work taxis, and be that male presence in my life—helped shape my whole view on maleness and fatherhood.” He encourages single mothers to be creative and seek out mentorship programmes and sporting groups within their respective communities. “You have to do the work,” he nodded. “A consistent male presence communicates safety and stability to a child. It’s not about doing it alone; it’s about creating opportunities for positive male influences.” Bringing musical healing Gordon revealed his artistry and social work are deeply intertwined. “Music is therapy for me. It allows me to deal with real-life dynamics like love, loss, and family,” he shared. “I can’t be preaching one thing in social work and then saying something different in my music.” He explained how songs like “Family Vibes” reflect his ethos. The two-time National Calypso Monarch has coined his unique mix of danceable music with strong messages (Jiggy Calypso) and has previously released “Charlsie” (2024), “Maths eh Mathsing” (2023), “Wha Yuh Doin” (2017) and “I Believe” (2015), among others. “It’s about choosing to spend time with your family, to create those moments that matter. I say in the song, ‘When you make your money and your money’s tall, it’s them you should have a ball with.’ That’s real,” he emoted. “It’s about making time for family despite life’s pressures.” The musical therapy flows both ways, he added, revealing that while he aims to bring soothing to others with his melodies and harmonies, he often finds the reverse is true. “I therapise myself through my music, but it’s also about sharing a message. The success it brings is irrelevant because it’s what I truly live by and believe in,” he concluded. “Christmas, in particular, is a rejuvenating time—the energy, the air, everything lends itself to connection.”INDIANAPOLIS — Marcus Harper II available for the Big Ten championship game. The Oregon offensive guard, who has missed three games due to a knee injury, and defensive tackle Keyon Ware-Hudson are not listed on UO’s player availability report for Saturday’s game against No. 3 Penn State at Lucas Oil Stadium. It comes as no surprise for Harper, who indicated as such earlier Saturday. Cornerback Jahlil Florence (knee) defensive linemen My’Keil Gardner (right foot) are out. Defensive tackle Tionne Gray (unspecified) is questionable. Offensive lineman Matthew Bedford (knee), receiver Kyler Kasper (right foot) and tight end Roger Saleapaga (knee) are out for the remainder of the season. Big Ten championship: No. 1 Oregon (12-0) vs. No. 3 Penn State (11-1) When: Saturday, Dec. 7 Time: 5 p.m. PT Where: Lucas Oil Stadium, Indianapolis TV channel: CBS Stream: You can watch this game live for FREE with Fubo (free trial) or with DirecTV Stream (free trial). If you already have a cable provider, use your login information to watch this game on cbssports.com . Oregon Ducks football 2024 season schedule, scores Sign up for The Ducks Beat newsletter Penn State’s Dakaari Nelson is questionable and Kevin Winston Jr., Kaden Saunders, Cam Wallace, Keon Wylie, Zuriah Fisher, Alonzo Ford, Kaleb Artis, Anthony Donkoh and Andrew Rappleyea remain out for the Nittany Lions. Harrison Wallace, who was questionable against Maryland, and Elliot Washington, who was out last week, are not listed. -- James Crepea covers the Oregon Ducks and Big Ten. Listen to the Ducks Confidential podcast or subscribe to the Ducks Roundup newsletter .Ancient meets modern as a new subway in Greece showcases archaeological treasures
COLUMBUS, Ohio--(BUSINESS WIRE)--Dec 13, 2024-- Dr. Johney Green Jr. has been named the next Laboratory Director at Savannah River National Laboratory (SRNL). He currently serves as the Associate Laboratory Director for mechanical and thermal engineering sciences at the National Renewable Energy Laboratory (NREL). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241213541679/en/ Dr. Johney Green Jr. (Photo: Business Wire) SRNL, a multi-program national laboratory with an annual operating budget of about $400 million, is a leading research and development institution for the Offices of Environmental Management and Legacy Management at the Department of Energy (DOE) and the Weapons and Nonproliferation programs for the National Nuclear Security Administration (NNSA). “We are thrilled to have Johney become the new leader of SRNL,” said Juan Alvarez, Battelle’s Executive Vice President for National Laboratory Management and Operations and Chair of the Board of Directors at Battelle Savannah River Alliance , LLC (BSRA). “We are confident that he is the right person to lead this exceptional national asset with a legacy of delivering impactful solutions for environmental, energy, and security challenges.” At NREL Green currently oversees NREL's transportation, buildings, wind, water, geothermal, advanced manufacturing, concentrating solar power, and Arctic research programs, which encompass a portfolio of more than $300 million and a workforce of about 750. Directorate staff conduct research and development to enable technology innovations in the areas of energy efficiency, sustainable transportation, and renewable power. “I am honored and humbled by the opportunity to join the SRNL community and work alongside our dedicated staff and regional university partners” Green said. “Together, we will drive innovation, enhance the laboratory’s capabilities, and expand its contributions to national security, environmental sustainability, and energy resilience for the benefit of the nation.” Among his accomplishments at NREL, Green transformed the lab’s wind site into the Flatirons Campus and transitioned the campus from a single-program wind research site to a multiprogram research campus that is the foundational experimental platform for the DOE’s Advanced Research on Integrated Energy Systems (ARIES) initiative. Prior to his time at NREL, Green held several leadership roles at Oak Ridge National Laboratory (ORNL), where he served as director of the Energy and Transportation Science Division and group leader for fuels, engines, and emissions research. Green managed a broad science and technology portfolio and user facilities that made significant science and engineering advances in building technologies; sustainable industrial and manufacturing processes; fuels, engines, emissions, and transportation analysis; and vehicle systems integration. During his tenure as a division director, ORNL developed the Additive Manufacturing Integrated Energy (AMIE) demonstration project, a model of innovative vehicle-to-grid integration technologies and next-generation manufacturing processes. Early in his career, Green conducted combustion research to stabilize gasoline engine operation under extreme conditions. In the course of that research, he joined a team working with Ford Motor Co., seeking ways to simultaneously extend exhaust gas recirculation limits in diesel engines and reduce nitrogen oxide and particulate matter emissions. He continued this collaboration as a visiting scientist at Ford's Scientific Research Laboratory, conducting modeling and experimental research for advanced diesel engines designed for light-duty vehicles. On assignment to the U.S. Department of Energy's Vehicle Technologies Office, Green also served as technical coordinator for the 21st Century Truck Partnership. He also contributed to a dozen of ORNL's 150-plus top scientific discoveries. Green is a fellow of the American Association for the Advancement of Science and an SAE International fellow. He serves on the Defense Science Board and several advisory boards including those at the Georgia Institute of Technology and the University of Memphis. Green is also the former chairman of the board for the National GEM Consortium and has been an invited participant in several National Academy of Engineering programs. Green has received several awards during his career and holds two U.S. patents in combustion science. Additionally, he has an h-index of 34 with more than 4,500 citations, is the lead or co-author of several technical publications, and has given many invited, keynote, and plenary presentations. Green holds a bachelor's degree in mechanical engineering from the University of Memphis and a master's and doctorate in mechanical engineering from the Georgia Institute of Technology. About Battelle Savannah River Alliance, LLC Battelle Savannah River Alliance, LLC (BSRA), a not-for-profit limited liability company, manages and operates SRNL for the DOE. BSRA board leadership includes Battelle Memorial Institute, Clemson University, University of South Carolina, South Carolina State University, University of Georgia, and Georgia Institute of Technology. Battelle Memorial Institute and the five universities are joined in partnership with preferred subcontractors TechSource and Longenecker & Associates with the singular purpose of maintaining SRNL as a best-in-class national laboratory. About Battelle Every day, the people of Battelle apply science and technology to solving what matters most. At major technology centers and national laboratories around the world, Battelle conducts research and development, designs and manufactures products, and delivers critical services for government and commercial customers. Headquartered in Columbus, Ohio since its founding in 1929, Battelle serves the national security, health and life sciences, and energy and environmental industries. For more information, visit www.battelle.org . View source version on businesswire.com : https://www.businesswire.com/news/home/20241213541679/en/ CONTACT: SRNL ContactChris O’Neil, APR, Director, Office of Communications Savannah River National Laboratory (803) 725-1004 (O) or (803) 679-7788 (M) or at chris.o'neil@srnl.doe.govBattelle ContactKaty Delaney at (614) 424-7208 or atdelaneyk@battelle.org or contact T.R. Massey at (614) 424-5544 or atmasseytr@battelle.org KEYWORD: OHIO GEORGIA UNITED STATES NORTH AMERICA INDUSTRY KEYWORD: AUTOMOTIVE MANUFACTURING MANUFACTURING DEFENSE ENVIRONMENT OTHER SCIENCE AUTOMOTIVE RESEARCH OTHER DEFENSE OTHER POLICY ISSUES SCIENCE PUBLIC POLICY/GOVERNMENT OIL/GAS ALTERNATIVE ENERGY ENERGY OTHER MANUFACTURING GENERAL AUTOMOTIVE NUCLEAR ENGINEERING SOURCE: Battelle Copyright Business Wire 2024. PUB: 12/13/2024 01:30 PM/DISC: 12/13/2024 01:30 PM http://www.businesswire.com/news/home/20241213541679/en
At a glance Expert's Rating Pros Generous selection of ports Long battery life Good performance Cons Bad trackpad The Intel version is faster Arm PCs still have compatibility drawbacks Dim display Our Verdict Price When Reviewed This value will show the geolocated pricing text for product undefined Best Pricing Today The Acer Swift 14 AI looks like an unimposing laptop that could easily be mistaken for any number of machines in Acer's lineup. It has a secret inside, though. The Swift 14 AI is Acer's first Arm-based notebook, running on Qualcomm's Snapdragon X Elite processor. Laptops have changed a lot in the last few years as Arm-based chips have finally gotten powerful enough to run Windows. The Acer Swift 14 AI might not be the best representative of that change, though. The Acer Swift 14 AI is slim and efficient, running for ages before it needs to recharge. It also has a pretty generous selection of ports for a thin-and-light laptop. However, the trackpad is below average, and there's entirely too much bloatware. There are also issues that aren't Acer's fault—emulated apps don't always work right and some hardware won't play nice with Arm PCs. For the right price, the Acer Swift 14 AI can be a fine entrée to the world of Copilot+ PCs, but that price is not the MSRP. Acer Swift 14 AI: Specs and features You won't have to make any difficult choices when purchasing the Acer Swift 14 AI. There are only two variants of the machine, one with a touchscreen and the other without. Both display options are the same 2560×1600 IPS. The touch version (which I have been testing) is $1,099.99, and the non-touch version is $1,049.99. The specifications are identical, so there's no reason not to get the touch version for an extra $50. Inside, the Acer Swift 14 AI sports a Qualcomm Snapdragon X Elite (X1E-78-100), a 12-core Arm processor that we've seen in laptops like Dell XPS 13 (9345). The capable Oryon CPU cores are backed up by an integrated Adreno... Author , Ryan Whitwam , .Wp-Block-Co-Authors-Plus-Coauthors.Is-Layout-Flow , Class , Wp-Block-Co-Authors-Plus , Display Inline , .Wp-Block-Co-Authors-Plus-Avatar , Where Img , Height Auto Max-Width , Vertical-Align Bottom .Wp-Block-Co-Authors-Plus-Coauthors.Is-Layout-Flow .Wp-Block-Co-Authors-Plus-Avatar
TAIPEI , Dec. 6, 2024 /PRNewswire/ -- Cordyceps Sunshine Biotech Holdings Co., Ltd. 【C.S 】 Group , Taiwan's largest chain specializing in Taiwanofungus products, has officially announced its entry into the global pet medication market with a groundbreaking new drug. On November 30, 2024 , the company co-hosted the "Taiwanofungus Fungal Technology and Pharmacological Research Progress Seminar" in Taipei with the Chinese Herbal Fungi Industry Research and Development Association (CHFIRDA). During the seminar, 【C.S 】 Group revealed plans to produce a topical ointment using Antcin A , a key compound extracted from Taiwanofungus , aiming to address the demand in the global steroid-based pet medication market. Extraction and purification of the key compound in Taiwanofungus, Antcin A. Vincent Liu , director at 【C.S 】 Group , highlighted the company's unique position as one of the few biotech startups capable of vertically integrating the entire production chain-from fungal strain development, cultivation, extraction, and purification to large-scale production and distribution. It is expected that the active ingredients will be further extracted, making it an ideal candidate for the development of botanical new drugs. A report by Market Research Engine projects the global botanical drugs market to reach $47.4 billion by 2028, with a compound annual growth rate (CAGR) of 6%. Antcin A, a signature sterol compound derived from Taiwanofungus, serves as a precursor for many bioactive compounds but is challenging to extract due to its scarcity in wild strains. Leveraging proprietary breeding techniques and patent-protected cultivation methods, 【C.S 】 Group has successfully optimized the production of Antcin A, enabling scalable extraction and purification. (Left) Vincent Liu, Director of 【C.S】 Group; (Right) Dalan Huang, President of 【C.S】 Group Dr. Jia-Xin Huang , a renowned Taiwanofungus expert, The effects of Antcin A have been recognized by the industry for a long time. However, the extraction process requires a large amount of Taiwanofungus raw materials, which is very costly and few industry players can overcome it. As a result, the market demand far exceeds the supply. If it is to be commercialized in the short term, it is very suitable to be introduced into the pet external preparation market first. Dr. Chiao Li , a U.S. listing advisor for 【C.S 】 Group , emphasized the immense potential of the global pet market, particularly in North America . According to the American Pet Products Association (APPA), as of 2017-2018, there were 84.6 million pet-owning households in the U.S., with 94.2 million cats and 89.7 million dogs. The pet industry is projected to reach $150 billion by 2024. Furthermore, Asia has emerged as a fast-growing pet market, with substantial growth momentum. In developed regions like Europe and the U.S., spending on pets-including medical care, medications, food, and insurance-is well-established. As pet ownership rises globally, fueled by aging populations and declining birth rates, demand for pet medications is expected to increase. Innovative Solutions for a Growing Market Dalan Huang , President of 【C.S 】 Group , cited a Research Nester report projecting the global pet medication market to reach $22.58 billion by 2024, with a CAGR exceeding 9.7% through 2036, potentially surpassing $69.8 billion . Steroids remain a common treatment option but are often stigmatized due to their side effects. With the anti-inflammatory efficacy of Antcin A, 【C.S 】 Group aims to introduce a novel steroid alternative that reduces reliance on conventional steroids while minimizing side effects, a solution likely to appeal to both veterinarians and pet owners. The Taiwanese pet medication market is valued at approximately NT$60 billion , with NT$12 billion attributed to livestock and NT$48 billion to pets. Taiwan's Institute for Economic Research (TIER) estimates that the pet population will reach 4 million by 2025, ensuring steady market growth. Promising Growth in the U.S. Capital Market In recent years, the U.S. capital market has introduced pet-themed ETFs, reflecting the long-term revenue potential of the pet industry, where the average pet lifespan of 10-15 years provides stable income streams resilient to economic fluctuations. 【C.S 】 Group 's classification in the U.S. stock market as a company specializing in medicinal plants is supported by its exclusive cultivation techniques for Taiwan's native Taiwanofungus . With large-scale production facilities in Taiwan , the company has achieved a CAGR of 41% in the Taiwanese market between 2023 and 2024. Building on the Asia pacific herbal health and pharmaceutical markets, 【C.S 】 Group 's expansion into the global pet steroid medication market is set to drive significant revenue growth with a bright outlook ahead.PDA Terminal Market 2024: A Decade of Phenomenal Growth Ahead 12-13-2024 07:26 PM CET | Business, Economy, Finances, Banking & Insurance Press release from: Prudent Markets PDA Terminal Market The PDA Terminal Market 2024-2023 report provides a comprehensive analysis of Types (PDA Barcode Scanner, PDA RFID Reader), Application (Retail and Wholesale, Logistics and Warehousing, Industrial Manufacturing, Healthcare, Government, Others), Analysis of Industry Trends, Growth, and Opportunities, R&D landscape, Data security and privacy concerns Risk Analysis, Pipeline Products, Assumptions, Research Timelines, Secondary Research and Primary Research, Key Insights from Industry Experts, Regional Outlook and Forecast, 2024-2032. Major Players of PDA Terminal Market are: Zebra, Honeywell, Bluebird, Urovo Technology, Datalogic, Newland, CASIO, Denso Wave, Panasonic, Seuic, Shenzhen Chainway, iData, Handheld Group, Supoin, Keyence, Cipherlab Get PDF Sample Report Now! @ https://www.prudentmarkets.com/sample-request/9165241/ Apersonal digital assistant(PDA), also known as a handheld PC, is a variety mobile device which functions as a personal information manager. This report provides a deep insight into the global PDA Terminal market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc. The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global PDA Terminal Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market. Segmentation of PDA Terminal Market- By Type PDA Barcode Scanner, PDA RFID Reader By Application Retail and Wholesale, Logistics and Warehousing, Industrial Manufacturing, Healthcare, Government, Others Geographic Segmentation -North America (USA, Canada, Mexico) -Europe (Germany, UK, France, Russia, Italy, Rest of Europe) -Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific) -South America (Brazil, Argentina, Columbia, Rest of South America) -The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA) Prudent Markets provides attractive discounts that fit your needs. Customization of the reports as per your requirement is also offered. Get in touch with our sales team, who will guarantee you a report that suits your needs. Speak To Our Analyst For A Discussion On The Above Findings, And Ask For A Discount On The Report @ https://www.prudentmarkets.com/discount-request/9165241/ Key Benefits of the Report: This study presents the analytical depiction of the PDA Terminal Industry along with the current trends and future estimations to determine the imminent investment pockets. The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the PDA Terminal Market share. The current market is quantitatively analyzed from to highlight the Global Gardening Pots Market growth scenario. Porter's five forces analysis illustrates the potency of buyers & suppliers in the market. The report provides a detailed PDA Terminal Market analysis based on competitive intensity and how the competition will take shape in coming years. Key poles of the TOC: Chapter 1 PDA Terminal Market Business Overview Chapter 2 Major Breakdown by Type Chapter 3 Major Application Wise Breakdown (Revenue & Volume) Chapter 4 Manufacture Market Breakdown Chapter 5 Sales & Estimates Market Study Chapter 6 Key Manufacturers Production and Sales Market Comparison Breakdown Chapter 8 Manufacturers, Deals and Closings Market Evaluation & Aggressiveness Chapter 9 Key Companies Breakdown by Overall Market Size & Revenue by Type Chapter 11 Business / Industry Chain (Value & Supply Chain Analysis) Chapter 12 Conclusions & Appendix The report covers the competitive analysis of the market. As the demand is driven by a buyer's paying capacity and the rate of item development, the report shows the important regions that will direct growth. This section exclusively shares insight into the budget reports of big-league members of the market helping key players and new entrants understand the potential of investments in the Global PDA Terminal Market. It can be better employed by both traditional and new players in the industry for complete know-how of the market. For In-Depth Competitive Analysis - Purchase this Report now at a Complete Table of Contents (Single User License) @ https://www.prudentmarkets.com/checkout/?id=9165241&license_type=su Free Customization on the basis of client requirements on Immediate purchase: 1- Free country-level breakdown of any 5 countries of your interest. 2- Competitive breakdown of segment revenue by market players. Customization of the Report: This report can be customized to meet the client's requirements. Please connect with our sales team (sales@prudentmarkets.com), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +91 83560 50278 || USA/Canada(Toll Free): 1800-601-6071 to share your research requirements. In conclusion, the PDA Terminal Market report is a genuine source for accessing the research data which is projected to exponentially grow your business. The report provides information such as economic scenarios, benefits, limits, trends, market growth rates, and figures. SWOT analysis and PESTLE analysis is also incorporated in the report. Contact Us: Allan Carter Andheri, Maharashtra, 400102 USA/Canada(Toll Free): 1800-601-6071 Direct Line: +91 83560 50278 Mail: sales@prudentmarkets.com Web: www.prudentmarkets.com About Us: We are leaders in market analytics, business research, and consulting services for Fortune 500 companies, start-ups, financial & government institutions. Since we understand the criticality of data and insights, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available. To be at our client's disposal whenever they need help on market research and consulting services. We also aim to be their business partners when it comes to making critical business decisions around new market entry, M&A, competitive Intelligence and strategy. This release was published on openPR.After-hours movers: Marvell Technology, Salesforce, Okta and more
The US stock market is currently at a point that its investors are basking in glory at some of the most amazing returns showcased through the bull run in the past two years. As of now, the US stock market has recorded a historically high PE ratio, something that has only been seen twice in the past few decades, as per reports. Is the US stock market close to making another history? It looks like the PE ratio in recent times has now touched 22.3, which is a level that was last seen during the time when the dot-com bubble occurred, as well as the time of the Covid-19 pandemic. Both these phases are not very memorable for the US stock market, which is the reason why market experts are also advising investors to take not of the issue, and put their money into the stock market wisely. With Donald Trump coming to power in January, there are also chances that his arrival may bring in a stock market crash, with some his economic plans being reportedly inflationary in nature. Donald Trump is currently standing at such an economical juncture, that his tariffs, which he has planned on imposing, could bring in inflation into the US economy , and the stock markets may have to face a wrath of this action. FAQs: Is S&P 500 a stock index? Yes, the S&P 500 is a very US stock market index which analyzes the performance of 500 of the biggest companies listed on exchanges in the US. Which is one of the most followed stock indices? S&P 500 is one of the most popular stock index in the US, and has a solid traffic of financial inflow and outflow. Artificial Intelligence(AI) ChatGPT Mastery from Zero to Hero: The Complete AI Course By - Metla Sudha Sekhar, IT Specialist and Developer View Program Web Development Maximizing Developer Productivity: The Pomodoro Technique in Practice By - Prince Patni, Software Developer (BI, Data Science) View Program Web Development Java 21 Essentials for Beginners: Build Strong Programming Foundations By - Metla Sudha Sekhar, IT Specialist and Developer View Program Marketing Modern Marketing Masterclass by Seth Godin By - Seth Godin, Former dot com Business Executive and Best Selling Author View Program Soft Skills Cross-Cultural Communication Mastery: Connect with Confidence By - Prince Patni, Software Developer (BI, Data Science) View Program Web Development Intermediate Java Mastery: Method, Collections, and Beyond By - Metla Sudha Sekhar, IT Specialist and Developer View Program Finance A2Z Of Money By - elearnmarkets, Financial Education by StockEdge View Program Entrepreneurship From Idea to Product: A Startup Development Guide By - Dr. Anu Khanchandani, Startup Coach with more than 25 years of experience View Program Artificial Intelligence(AI) Generative AI for Dynamic Java Web Applications with ChatGPT By - Metla Sudha Sekhar, IT Specialist and Developer View Program Marketing Digital Marketing Masterclass by Pam Moore By - Pam Moore, Digital Transformation and Social Media Expert View Program Web Development A Comprehensive ASP.NET Core MVC 6 Project Guide for 2024 By - Metla Sudha Sekhar, IT Specialist and Developer View Program Finance Financial Literacy for Non-Finance Executives By - CA Raja, Chartered Accountant | Financial Management Educator | Former AVP - Credit, SBI View Program Entrepreneurship Marketing & Sales Strategies for Startups: From Concept to Conversion By - Dr. Anu Khanchandani, Startup Coach with more than 25 years of experience View Program Artificial Intelligence(AI) Java Programming with ChatGPT: Learn using Generative AI By - Metla Sudha Sekhar, IT Specialist and Developer View Program Finance Tally Prime & GST Accounting: Complete Guide By - CA Raj K Agrawal, Chartered Accountant View Program Legal Complete Guide to AI Governance and Compliance By - Prince Patni, Software Developer (BI, Data Science) View Program Finance A2Z Of Finance: Finance Beginner Course By - elearnmarkets, Financial Education by StockEdge View Program Web Development Advanced Java Mastery: Object-Oriented Programming Techniques By - Metla Sudha Sekhar, IT Specialist and Developer View Program Entrepreneurship Building Your Winning Startup Team: Key Strategies for Success By - Dr. Anu Khanchandani, Startup Coach with more than 25 years of experience View Program Artificial Intelligence(AI) AI for Everyone: Understanding and Applying the Basics on Artificial Intelligence By - Ritesh Vajariya, Generative AI Expert View Program Marketing Digital marketing - Wordpress Website Development By - Shraddha Somani, Digital Marketing Trainer, Consultant, Strategiest and Subject Matter expert View Program Office Productivity Mastering Google Sheets: Unleash the Power of Excel and Advance Analysis By - Metla Sudha Sekhar, IT Specialist and Developer View Program Web Development Django & PostgreSQL Mastery: Build Professional Web Applications By - Metla Sudha Sekhar, IT Specialist and Developer View Program Strategy Succession Planning Masterclass By - Nigel Penny, Global Strategy Advisor: NSP Strategy Facilitation Ltd. View Program Web Development 12-Factor App Methodology: Principles and Guidelines By - Prince Patni, Software Developer (BI, Data Science) View Program Marketing Future of Marketing & Branding Masterclass By - Dr. David Aaker, Professor Emeritus at the Haas School of Business, UC Berkeley, Author | Speaker | Thought Leader | Branding Consultant View Program (You can now subscribe to our Economic Times WhatsApp channel )
From learner to leader: BISP sets a global standard
Evolv Receives Expected Nasdaq Delinquency Notification
Bleichroeder Acquisition Corp. I Announces the Separate Trading of its Class A Ordinary Shares and Rights, Commencing December 2, 2024
Phase 3 Study Results Demonstrated Three Year, Disease-Free Survival of 96% THOUSAND OAKS, Calif. , Dec. 7, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data demonstrating that adding BLINCYTO ® (blinatumomab) to chemotherapy significantly improves disease-free survival (DFS) in newly diagnosed pediatric patients with National Cancer Institute (NCI) standard risk (SR) B-cell acute lymphoblastic leukemia (B-ALL) of average or higher risk of relapse. The data are from a Phase 3 study (AALL1731) conducted by the Children's Oncology Group. The results were simultaneously published in the New England Journal of Medicine and will be presented during the plenary session on Sunday, Dec. 8 , at 2 p.m. PT at the 66 th American Society of Hematology (ASH) Annual Meeting & Exposition in San Diego . "Over the last decade, BLINCYTO has reshaped the treatment landscape for B-ALL, offering a critical lifeline for thousands of adult and pediatric patients," said Jay Bradner , M.D., executive vice president of Research and Development and chief scientific officer at Amgen. "These powerful new data leave us little doubt about the profound impact of this medicine for a large number of children affected by this disease. We are grateful to the Children's Oncology Group, along with the patients, families and clinical teams, for their dedication and partnership in advancing this critical study to improve the lives of children with cancer." Based on the results of the first pre-specified interim analysis for efficacy, the study met its primary endpoint of DFS and study randomization was terminated early based on the recommendation from the data and safety monitoring committee due to the benefit observed in the BLINCYTO arm compared to the chemotherapy-only arm. Overall, the 3-year DFS was 96.0% for patients treated with chemotherapy plus BLINCYTO compared to 87.9% for those treated with only chemotherapy. The hazard ratio (HR) was 0.39 [95% confidence interval (CI) 0.24-0.64], indicating a 61% reduction in the risk of disease relapse, secondary malignant neoplasm or remission death with BLINCYTO. At 3 years, more patients remained alive and cancer free when treated with BLINCYTO plus chemotherapy compared to chemotherapy alone. "The AALL1731 study results are truly practice-changing, further solidifying blinatumomab's role as the standard of care for a large number of children with B-ALL," said Sumit Gupta , M.D., Ph.D., FRCPC, co-chair of the Children's Oncology Group AALL1731 study and oncologist and clinician investigator, Division of Haematology/Oncology at The Hospital for Sick Children (SickKids) and associate professor of pediatrics at the University of Toronto . "These breakthrough data showing a significant improvement in disease-free survival are poised to bring substantial clinical value to children with newly diagnosed B-ALL." The addition of BLINCYTO to chemotherapy in standard risk patients resulted in outcomes similar to those previously achieved in only the most favorable pediatric risk subsets. Among SR-Average patients, 3-year DFS was 97.5% for patients treated with BLINCYTO compared to 90.2% for those treated with only chemotherapy (HR 0.33, CI 0.15-0.69). For SR-High patients, 3-year DFS was 94.1% for those treated with BLINCYTO compared to 84.8% for those treated with only chemotherapy (HR 0.45, 95% CI 0.24-0.85). "Relapsed ALL remains a major cause of pediatric cancer mortality, with nearly half of the relapses occurring in children with standard-risk B-ALL," said Rachel E. Rau , M.D., co-chair of the Children's Oncology Group AALL1731 study, pediatric hematologist-oncologist at Seattle Children's Hospital and associate professor of pediatrics at the University of Washington . "These findings underscore the progress made with blinatumomab in preventing relapse and support its role as a critical addition to current therapeutic strategies." Safety results are consistent with the known safety profile of BLINCYTO. BLINCYTO has demonstrated a positive balance of benefits and risks, with only 0.3% of first courses associated with Grade 3+ cytokine release syndrome (CRS) and 0.7% with seizures. A higher risk of infections was observed in the BLINCYTO arm. These results provide the first evidence supporting BLINCYTO for use in the consolidation phase in newly diagnosed pediatric Philadelphia chromosome-negative (Ph-) B-ALL patients. This groundbreaking first-in-class Bispecific T-cell Engager (BiTE ® ) therapy is now backed by additional evidence reinforcing its role in redefining a standard of care for both adult and pediatric patients, starting from one month old, regardless of measurable residual disease (MRD) status. The findings further establish BLINCYTO as a versatile first-line consolidation therapy across all ages and treatment backbones. The NCI's Cancer Therapy Evaluation Program (CTEP), which sponsored the study will share data with the U.S. Food and Drug Administration as part of their ongoing communications relating to the trial. About The Children's Oncology Group The Children's Oncology Group (childrensoncologygroup.org), a member of the NCI National Clinical Trials Network (NCTN), is the world's largest organization devoted exclusively to childhood and adolescent cancer research. The Children's Oncology Group unites over 10,000 experts in childhood cancer at more than 200 leading children's hospitals, universities and cancer centers across North America , Australia , New Zealand and Saudi Arabia in the fight against childhood cancer. Today, more than 80% of the 15,000 children and adolescents diagnosed with cancer each year in the United States are cared for at Children's Oncology Group member institutions. Research performed by Children's Oncology Group institutions over the past 50 years has transformed childhood cancer from a virtually incurable disease to one with a combined 5-year survival rate of 86%. The Children's Oncology Group's mission is to improve the cure rate and outcomes for all children with cancer. About AALL1731 (NCT03914625) The AALL1731 study was a Phase 3 randomized trial to determine if two non-sequential cycles of BLINCYTO added to chemotherapy improved disease-free survival (DFS) in children with newly diagnosed pediatric National Cancer Institute (NCI) standard risk (SR) B-cell acute lymphoblastic leukemia (B-ALL). The study enrolled 4,264 newly diagnosed NCI SR B-ALL patients, of whom 2,334 were risk stratified at the end of induction therapy as either SR-Average or SR-High. At the first planned interim efficacy analysis (data cutoff June 30, 2024 ), 1,440 of the eligible and evaluable patients had been randomized. The AALL1731 study was designed and conducted independently from industry. The Cancer Therapy Evaluation Program (CTEP) of the NCI sponsored the trial and provided funding to the Children's Oncology Group to conduct the study. NCI is part of the National Institutes of Health (NIH). In addition, Amgen provided BLINCYTO and support through an NCI Cooperative Research and Development Agreement. About Acute Lymphoblastic Leukemia (ALL) ALL, also known as acute lymphoblastic leukemia, is a fast-growing type of blood cancer that develops in the bone marrow and can sometimes spread to other parts of the body, including the lymph nodes, liver, spleen and central nervous system. ALL is a rare disease, with an estimated 6,550 new cases, affecting both children and adults, diagnosed in the U.S. in 2024. 1 B-ALL begins in immature cells that would normally develop into B-cell lymphocytes, which are white blood cells that grow in bone marrow. 2,3 B-ALL is the most common type of ALL, constituting approximately 75% of cases in adults and approximately 88% in children, the most common cancer in children. 4,5 About BLINCYTO ® (blinatumomab) BLINCYTO is the first globally approved Bispecific T-cell Engager (BiTE ® ) immuno-oncology therapy that targets CD19 surface antigens on B cells. BiTE ® molecules fight cancer by helping the body's immune system detect and target malignant cells by engaging T cells (a type of white blood cell capable of killing other cells perceived as threats) to cancer cells. By bringing T cells near cancer cells, the T cells can inject toxins and trigger cancer cell death (apoptosis). BiTE ® immuno-oncology therapies are currently being investigated for their potential to treat a wide variety of cancers. BLINCYTO was granted Breakthrough Therapy and Priority Review designations by the U.S. FDA and is approved in the U.S. for the treatment of: In the European Union (EU), BLINCYTO is indicated as monotherapy for the treatment of: BLINCYTO ® IMPORTANT SAFETY INFORMATION WARNING: CYTOKINE RELEASE SYNDROME and NEUROLOGICAL TOXICITIES including IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME Contraindications BLINCYTO ® is contraindicated in patients with a known hypersensitivity to blinatumomab or to any component of the product formulation. Warnings and Precautions Adverse Reactions Dosage and Administration Guidelines INDICATIONS BLINCYTO ® (blinatumomab) is indicated for the treatment of CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adult and pediatric patients one month and older with: Please see BLINCYTO ® full Prescribing Information , including BOXED WARNINGS. About Bispecific T-Cell Engager (BiTE ® ) Technology BiTE technology is a targeted immuno-oncology platform that is designed to engage a patient's own T cells to any tumor-specific antigen, activating the cytotoxic potential of T cells to eliminate detectable cancer. The BiTE immuno-oncology platform has the potential to treat different cancer types through tumor-specific antigens. The BiTE platform has a goal of leading to off-the-shelf solutions, which have the potential to make innovative T-cell treatment available to all providers when their patients need it. For more than a decade, Amgen has been advancing this innovative technology, which has demonstrated strong efficacy in hematological malignancies and now a solid tumor with the approval of IMDELLTRA. Amgen remains committed to progressing multiple BiTE molecules across a broad range of hematologic and solid tumor malignancies, paving the way for additional applications in more tumor types. Amgen is further investigating BiTE technology with the goal of enhancing patient experience and therapeutic potential. To learn more about BiTE technology, visit BiTE ® Technology 101 . About Amgen Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases. In 2024, Amgen was named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes, among other external recognitions . Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average ® , and it is also part of the Nasdaq-100 Index ® , which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization. For more information, visit Amgen.com and follow Amgen on X , LinkedIn , Instagram , TikTok , YouTube and Threads . Amgen Forward-Looking Statements This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeiGene, Ltd. or Kyowa Kirin Co., Ltd.), the performance of Otezla ® (apremilast) (including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), Amgen's acquisitions of Teneobio, Inc., ChemoCentryx, Inc., or Horizon Therapeutics plc (including the prospective performance and outlook of Horizon's business, performance and opportunities, any potential strategic benefits, synergies or opportunities expected as a result of such acquisition, and any projected impacts from the Horizon acquisition on Amgen's acquisition-related expenses going forward), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems on Amgen's business, outcomes, progress, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including its most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise. No forward-looking statement can be guaranteed and actual results may differ materially from those Amgen projects. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for Amgen to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and Amgen expects similar variability in the future. Even when clinical trials are successful, regulatory authorities may question the sufficiency for approval of the trial endpoints Amgen has selected. Amgen develops product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as Amgen may have believed at the time of entering into such relationship. Also, Amgen or others could identify safety, side effects or manufacturing problems with its products, including its devices, after they are on the market. Amgen's results may be affected by its ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing its products and global economic conditions. In addition, sales of Amgen's products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, Amgen's research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Amgen's business may be impacted by government investigations, litigation and product liability claims. In addition, Amgen's business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If Amgen fails to meet the compliance obligations in the corporate integrity agreement between Amgen and the U.S. government, Amgen could become subject to significant sanctions. Further, while Amgen routinely obtains patents for its products and technology, the protection offered by its patents and patent applications may be challenged, invalidated or circumvented by its competitors, or Amgen may fail to prevail in present and future intellectual property litigation. Amgen performs a substantial amount of its commercial manufacturing activities at a few key facilities, including in Puerto Rico, and also depends on third parties for a portion of its manufacturing activities, and limits on supply may constrain sales of certain of its current products and product candidate development. An outbreak of disease or similar public health threat, such as COVID-19, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for Amgen's manufacturing activities, the distribution of Amgen's products, the commercialization of Amgen's product candidates, and Amgen's clinical trial operations, and any such events may have a material adverse effect on Amgen's product development, product sales, business and results of operations. Amgen relies on collaborations with third parties for the development of some of its product candidates and for the commercialization and sales of some of its commercial products. In addition, Amgen competes with other companies with respect to many of its marketed products as well as for the discovery and development of new products. Further, some raw materials, medical devices and component parts for Amgen's products are supplied by sole third-party suppliers. Certain of Amgen's distributors, customers and payers have substantial purchasing leverage in their dealings with Amgen. The discovery of significant problems with a product similar to one of Amgen's products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on its business and results of operations. Amgen's efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology Amgen has acquired, may not be successful. There can be no guarantee that Amgen will be able to realize any of the strategic benefits, synergies or opportunities arising from the Horizon acquisition, and such benefits, synergies or opportunities may take longer to realize than expected. Amgen may not be able to successfully integrate Horizon, and such integration may take longer, be more difficult or cost more than expected. A breakdown, cyberattack or information security breach of Amgen's information technology systems could compromise the confidentiality, integrity and availability of Amgen's systems and Amgen's data. Amgen's stock price may be volatile and may be affected by a number of events. Amgen's business and operations may be negatively affected by the failure, or perceived failure, of achieving its environmental, social and governance objectives. The effects of global climate change and related natural disasters could negatively affect Amgen's business and operations. Global economic conditions may magnify certain risks that affect Amgen's business. Amgen's business performance could affect or limit the ability of the Amgen Board of Directors to declare a dividend or its ability to pay a dividend or repurchase its common stock. Amgen may not be able to access the capital and credit markets on terms that are favorable to it, or at all. Any scientific information discussed in this news release relating to new indications for Amgen's products is preliminary and investigative and is not part of the labeling approved by the U.S. Food and Drug Administration for the products. The products are not approved for the investigational use(s) discussed in this news release, and no conclusions can or should be drawn regarding the safety or effectiveness of the products for these uses. CONTACT: Amgen, Thousand Oaks Elissa Snook , 609-251-1407 (media) Justin Claeys , 805-313-9775 (investors) References View original content to download multimedia: https://www.prnewswire.com/news-releases/blincyto-blinatumomab-added-to-chemotherapy-significantly-improves-survival-in-newly-diagnosed-pediatric-patients-with-b-cell-precursor-acute-lymphoblastic-leukemia-b-all-302325381.html SOURCE AmgenGREENVILLE, S.C. (AP) — Pjay Smith Jr. scored 23 points as Furman beat Princeton 69-63 on Saturday. Smith also added eight rebounds and four steals for the Paladins (9-1). Garrett Hien scored 10 points while going 5 of 10 and 0 of 4 from the free-throw line and added seven rebounds. Nick Anderson shot 3 for 9 from beyond the arc to finish with nine points. The Tigers (7-4) were led by Xaivian Lee, who posted 16 points, seven rebounds and five assists. Princeton also got 13 points and four assists from Dalen Davis. Caden Pierce also had 11 points and four steals. NEXT UP Up next for Furman is a Saturday matchup with South Carolina State at home, and Princeton hosts Monmouth on Tuesday. The Associated Press created this story using technology provided by Data Skrive and data from Sportradar .